ProVerum Medical
ProVerum Medical is an Ireland-based medtech company that develops the ProVee System, an FDA-approved next-generation nitinol prostatic urethral stent for minimally invasive treatment of benign prostatic hyperplasia (BPH), commercially launched in the US in January 2026 and sold to urology practices and hospitals via direct enterprise field sales.
- Company typePrivate
- Founded2016
- HeadquartersDublin, Ireland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ProVerum Medical does
ProVerum Medical is a private medtech company founded in 2016 and headquartered in Dublin, Ireland, with a manufacturing facility in Galway, Ireland and a US commercial office in Plymouth, Minnesota. The company develops the ProVee System, a next-generation nitinol prostatic urethral stent designed as a First-Line Interventional Therapy (FIT) for benign prostatic hyperplasia (BPH). The ProVee System consists of three integrated components: a universally-sized nitinol stent with proprietary 3-D geometry that mirrors prostate anatomy and applies tuned radial force to open the obstructed urethra; a 16F flexible steerable delivery device with the same low profile as a diagnostic cystoscope; and a portable video processing unit (VPU) for direct visualization during deployment. The stent is fully reversible and can be retrieved at any time, and the universal-fit design eliminates the need for multiple size SKUs.
The system targets the US BPH treatment market covering over 12 million men and is sold through a direct enterprise field sales force to urology practices and hospitals. ProVerum received FDA approval for the ProVee System in December 2025 based on a 150-patient Pivotal Study (US, Canada, Ireland, 2022-2024) demonstrating significant symptom relief and safety over 12 months, and completed its first commercial US cases in January 2026. The company has raised approximately $80M in Series B financing (August 2025) led by MVM Partners, plus prior rounds including a €30M Series A (January 2022) and a €2.5M EU Horizon 2020 grant (2020). Leadership is concentrated among medtech executives with prior BPH and urology commercialization track records, including a CEO with two prior exits and a VP of Marketing who built the UroLift brand at NeoTract.
ProVerum Medical firmographics
Firmographics- Name
- ProVerum Medical
- Legal name
- ProVerum Limited
- Website
- https://proverummedical.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ProVerum Medical is an Ireland-based medtech company that develops the ProVee System, an FDA-approved next-generation nitinol prostatic urethral stent for minimally invasive treatment of benign prostatic hyperplasia (BPH), commercially launched in the US in January 2026 and sold to urology practices and hospitals via direct enterprise field sales.
- Ownership category
- akta.pro rank
Where ProVerum Medical is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices3 records
Markets served
ProVerum Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Marketing or Sales, Personnel
Revenue model
- ProVee System Hardware Sales: ProVerum generates revenue through the sale of its ProVee System, consisting of the nitinol prostatic urethral stent and the delivery device with video processing unit. The company commercialized the product in the United States following FDA approval in December 2025, with initial commercial cases completed in January 2026.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
ProVerum Medical product offering
Product offeringCore offering
ProVerum Medical develops and manufactures the ProVee System, a next-generation prostatic urethral stent for treating benign prostatic hyperplasia (BPH). The system consists of a universally sized nitinol stent with proprietary 3-D geometry, a 16F flexible steerable delivery device, and a portable video processing unit (VPU), designed to gently open the obstructed urethra without cutting, piercing, heating, or removing prostate tissue. The product is positioned as a First-Line Interventional Therapy (FIT) for BPH and is sold to urology practices and hospitals.
Product overview
ProVerum Medical offers a single unified product: the ProVee System for treating benign prostatic hyperplasia (BPH). The system comprises three integrated components — the ProVee nitinol stent (which uses 3-D geometry to mirror prostate anatomy and apply radial force to open the prostatic urethra), the ProVee Delivery Device (a 16F flexible sheath delivery system with steering lever and deployment trigger), and the ProVee VPU (video processing unit for visualization during the procedure). The system is designed as a First-Line Interventional Therapy that is minimally invasive, reversible, and provides universal fit for all indicated anatomies.
Differentiator
Problem solved
Functional benefit
Brands
- ProVee System: A next-generation prostatic urethral stent designed to treat benign prostatic hyperplasia (BPH). Uses a nitinol stent with 3-D geometry to gently open the obstructed urethra without cutting, piercing, heating, or removing prostate tissue. Features universal fit, atraumatic delivery, rapid recovery, and reversibility.
Products and services
- ProVee System The ProVee System is a next-generation prostatic urethral stent system for treating benign prostatic hyperplasia (BPH), consisting of a universally sized nitinol stent with proprietary 3-D geometry, a 16F flexible steerable delivery device, and a portable video processing unit (VPU). It is designed as a First-Line Interventional Therapy (FIT) for BPH that gently opens the obstructed urethra without cutting, piercing, heating, or removing prostate tissue, and is sold to urology practices and hospitals.
Quantifiable outcome
- Significant symptom relief and safety demonstrated over a 12-month period in clinical trials
Companies that use ProVerum Medical
Customer profileSegments2 records
Ideal customer profiles1 record
ProVerum Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ProVerum Medical partnerships and signals
Strategic signalScale indicators5 records
Recent moves8 records
Expansion highlights5 records
ProVerum Medical competitors and assessment
Company assessmentDirect peers
- Teleflex (UroLift): Teleflex acquired NeoTract for $1.1B in 2017 and now commercializes the UroLift System, the leading first-line interventional BPH therapy and ProVerum's most direct competitor for the same patient population and urology call point.
- PROCEPT BioRobotics: PROCEPT commercializes the Aquablation system, a robotic waterjet BPH treatment competing in the same minimally invasive interventional BPH space with similar urology-specialty positioning and a comparable growth profile.
- NeoTract (acquired by Teleflex): NeoTract pioneered first-line interventional BPH therapy with UroLift and was acquired by Teleflex for $1.1B in 2017, establishing the category and the commercial playbook ProVerum is following.
Broad incumbents
- Boston Scientific (Rezūm): Boston Scientific owns the Rezūm water-vapor BPH therapy (acquired via NxThera) and competes head-to-head with ProVerum in the minimally invasive BPH market while having far greater scale, distribution, and urology sales force coverage.
- Olympus (iTind): Olympus acquired Medi-Tate and distributes the iTind temporarily implanted nitinol device, a direct mechanical BPH therapy competing with ProVerum's ProVee stent in the same first-line interventional category.
- Coloplast: Coloplast is a major urology-focused medtech with established physician relationships in BPH and adjacent urological conditions, representing both a competitor and a likely strategic acquirer of ProVerum-like assets.
- Karl Storz (BPH laser portfolio): Karl Storz offers laser and surgical BPH solutions (e.g., enucleation technologies) sold to the same urology customer base as ProVerum, representing a broad incumbent in the BPH treatment continuum.
Emerging players
- Medi-Tate (Olympus subsidiary): Medi-Tate developed the iTind temporary nitinol device for BPH — a directly comparable mechanical approach using nitinol technology to reshape the prostatic urethra, now commercialized via Olympus.
- NxThera (acquired by Boston Scientific): NxThera developed the Rezūm water-vapor BPH therapy and was acquired by Boston Scientific — a near-identical strategic exit pathway (innovator → strategic acquisition) that ProVerum's board and management have track records of executing.
- SRS Medical: SRS Medical has developed alternative urological devices for lower urinary tract symptoms and represents a smaller-scale emerging player in the BPH/LUTS treatment space relevant to ProVerum.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ProVerum Medical social profiles
Digital presenceProVerum Medical compliance and trust
Trust signalCompliance1 record
ProVerum Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProVerum Medical leadership team
Management profileNumber of profiles
Profiles16 records
ProVerum Medical funding detail
Funding detailFunding overview
Funding rounds5 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProVerum Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProVerum Medical
What does ProVerum Medical do?
ProVerum Medical develops and manufactures the ProVee System, a next-generation prostatic urethral stent for treating benign prostatic hyperplasia (BPH). The system consists of a universally sized nitinol stent with proprietary 3-D geometry, a 16F flexible steerable delivery device, and a portable video processing unit (VPU), designed to gently open the obstructed urethra without cutting, piercing, heating, or removing prostate tissue. The product is positioned as a First-Line Interventional Therapy (FIT) for BPH and is sold to urology practices and hospitals.
Is ProVerum Medical a public or private company?
ProVerum Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was ProVerum Medical founded?
ProVerum Medical was founded in 2016. It employs 11 to 50 people.
Where is ProVerum Medical based?
ProVerum Medical is headquartered in Dublin, Ireland, in the Europe region.
How does ProVerum Medical make money?
One revenue line is on record: proVee System Hardware Sales.
Who are ProVerum Medical's main competitors?
Direct peers on record are Teleflex (UroLift), PROCEPT BioRobotics and NeoTract (acquired by Teleflex). Broad incumbents are Boston Scientific (Rezūm), Olympus (iTind), Coloplast and Karl Storz (BPH laser portfolio). Emerging players are Medi-Tate (Olympus subsidiary), NxThera (acquired by Boston Scientific) and SRS Medical.
Does ProVerum Medical have an API?
No public API is recorded for ProVerum Medical.